By adding the OneTouch Reveal® Plus app to your portfolio, you're putting data-driven technology to work for your members. The 24/7 digital coaching tool helps people with diabetes build better self-care skills that can result in greater glycemic control to positively impact A1C levels.
OneTouch Reveal® Plus supports key diabetes self-care behaviors identified by the ADA and AADE including:
- Glucose monitoring and medication alerts
- Healthy eating and exercise habits
- Immediate guidance to minimize related risks
Supportive AI Technology
The digital coach provides thousands of customized messages, for actionable, real-time guidance.
Manage Related Conditions
Features support self-care for hypertension and weight management, two conditions that often affect people with diabetes and lead to compounding care.
Care Team Support
The information provided by the SMART Visit Report can enable physicians to make informed prescribing decisions.
OneTouch Reveal® Plus supports key diabetes self-care behaviors identified by the ADA and AADE including:
- Glucose monitoring and medication alerts
- Healthy eating and exercise habits
- Immediate guidance to minimize related risks
Supportive AI Technology
The digital coach provides thousands of customized messages, for actionable, real-time guidance.
Manage Related Conditions
Features support self-care for hypertension and weight management, two conditions that often affect people with diabetes and lead to compounding care.
Care Team Support
The information provided by the SMART Visit Report can enable physicians to make informed prescribing decisions.
Studies in Type 2 diabetes
3-month randomized-controlled clinical trial
In a prospective, randomized, controlled study, Quinn et al. (Diabetes Technology and Therapeutics, 2008) found that individuals whose A1C levels were greater than or equal to 7.5% within most recent three months and received Welldoc’s software experienced an average decrease in A1C of 2.03%. Patients in the control group obtained an average A1C reduction of 0.68% (P < 0.02, one-tailed). Of the intervention patients, 84% had medications titrated or changed by their HCP compared to controls (23%, P = 0.002).
12-month randomized-controlled clinical trial
In a prospective, randomized, controlled study, Quinn et al. (Diabetes Care, 2011) found that, individuals with type 2 diabetes whose A1C levels were poorly controlled (>9.0%) or abnormal (7.5-8.9%) at the time of enrollment, and who were randomized to use a mobile phone app to help them manage their diabetes in addition to usual care, improved A1C by an average 1.9%, compared with 0.7% improvement in persons randomized to usual care alone, a difference of 1.2% (P < 0.001) over 12 months.
Testing the Relationship Between A1C Reduction and Cost Savings in Type 2 Diabetes
Welldoc funded a retrospective analysis in partnership with IBM Watson Health. They provided IBM Watson Health starting and ending A1C data from 3,000+ of their BlueStar® users. Documented A1C reductions associated with BlueStar® are correlated with cost differences associated with the factors listed below.
Hospitalizations, ER visits,
and HCP office visits
Cost of devices, supplies,
and medications
Cost of comorbid complications
of diabetes
Where did the data come from?
Claims data from patients in the IBM Watson Health's Market Scan Database, which captures claims data of more than 200 million individuals in the US.
What did the study find?
Once the patients were stratified by A1C band, the analysis was customized for the commercial sector and the medicare sector.
Learn More
Add the OneTouch Reveal® Plus app to your diabetes care portfolio today.
Clinically Proven
Outcomes
More than 40 peer-reviewed posters and publications highlight the value of the OneTouch Reveal® Plus app. Learn more about these publications on Welldoc.
Cost-Effective
Care
Estimated annual cost savings ranging from $1,824 - $5,244 per user resulting from managing glycemic variability3.
A Comprehensive
Solution
Additional features for blood pressure and weight management help members manage multiple chronic conditions and associated costs.
Real-Time
Guidance
The digital solution takes the guesswork out of meter readings with actionable coaching for high and low results.
A Trusted Leader in Diabetes Care
Class II Medical
Device
OneTouch Reveal® Plus is cleared by the FDA and designated as a Class II Medical Device.
Privacy &
Digital Security
OneTouch Reveal® Plus is SOC2 Certified, ISO13485 Certified and HIPAA Compliant.
Proven
Outcomes
Evidence-based clinical outcomes3,4. Economic outcome analysis conducted by IBM Watson Health.
Two easy-to-access options combine the power of the OneTouch Reveal® Plus app with products from our #1 selling brand.
New! OneTouch® Direct
Along with the power of digital coaching, members can now enjoy the convenience of free home delivery at no extra cost.
OneTouch® Preferred
Members can support their self-care with OneTouch Reveal® Plus while continuing to pick up supplies at the pharmacy, just as they do today.
What does investing in the OneTouch Reveal® Plus app look like?
Easy Payment
Options
We offer pricing options that fit your budget and performance indicator needs.
Flexible
Implementation
Our customized activation and engagement support provides seamless integration into your current program.
Innovation that
Supports Employees
We are constantly striving to delight and innovate with enhancements that evolve with your employees' needs.
Learn More
Add the OneTouch Reveal® Plus app to your diabetes care portfolio today.
Let's Connect
The OneTouch Reveal® Plus app, powered by BlueStar®, is indicated for use by patients aged 18 and older who have Type 1 or Type 2 diabetes and their healthcare providers. The app is not intended to replace the care provided by a licensed healthcare professional. The app should not be used by patients with gestational diabetes or patients using an insulin pump. BlueStar® is a Welldoc, Inc. patented system. The OneTouch Reveal® Plus app is manufactured by Welldoc, Inc.
1Quinn CC, et al. Diabetes Care. 2011:34:1934-1942.
2Quinn CC, et al. Diabetes Technol Ther. 2008;10:160-168
3Market Scan Analysis from Truven Analytics, an IBM Watson Health Company, for data collected between January 01, 2014 and December 31, 2015.
The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by LifeScan Scotland Ltd. and its affiliates is under license. Other trademarks and trade names are those of their respective owners.
US-OTRP-2000003
